Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma Sells 1,057 Shares of Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 1,057 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $10.02, for a total value of $10,591.14. Following the transaction, the president now owns 2,915,194 shares of the company’s stock, valued at $29,210,243.88. This represents a 0.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Songjiang Ma also recently made the following trade(s):

• On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.10, for a total value of $565.60.
• On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.16, for a total transaction of $9,560.56.
• On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.40, for a total transaction of $24,800.00.
• On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.50, for a total transaction of $25,000.00.
• On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.70, for a total value of $25,400.00.
• On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.27, for a total value of $24,540.00.
• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.82, for a total value of $21,640.00.
• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.05, for a total value of $22,100.00.

Gyre Therapeutics Stock Performance

Shares of NASDAQ GYRE opened at $10.52 on Wednesday. The firm’s 50-day simple moving average is $11.83 and its 200 day simple moving average is $12.66. Gyre Therapeutics, Inc. has a fifty-two week low of $8.26 and a fifty-two week high of $26.37.

Institutional Trading of Gyre Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in GYRE. FMR LLC bought a new position in shares of Gyre Therapeutics in the third quarter valued at approximately $47,000. Barclays PLC lifted its position in Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after purchasing an additional 6,855 shares during the period. State Street Corp boosted its stake in Gyre Therapeutics by 8.8% during the 3rd quarter. State Street Corp now owns 104,490 shares of the company’s stock valued at $1,310,000 after purchasing an additional 8,412 shares in the last quarter. Rhumbline Advisers acquired a new position in shares of Gyre Therapeutics during the 2nd quarter valued at $123,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Gyre Therapeutics during the 2nd quarter valued at $166,000. 23.99% of the stock is currently owned by institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.